Biblio

Author [ Title(Desc)] Type Year
Filters: Author is Verneris, Michael R  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
C
Gleason MK, Ross JA, Warlick ED, Lund TC, Verneris MR, Wiernik A, Spellman S, Haagenson MD, Lenvik AJ, Litzow MR, et al. CD16xCD33 bispecific killer cell engager (BiKE) activates NK cells from MDS patients against primary MDS and MDSC CD33+ targets. Blood. 2014.
Wagner JE, Ballen KKuhn, Zhang M-J, Allbee-Johnson M, Karanes C, Milano F, Verneris MR, Eapen M, Brunstein CG. Comparison of haploidentical and umbilical cord blood transplantation after myeloablative conditioning. Blood Adv. 2021.
D
Tsamadou C, Fürst D, Wang T, He N, Lee SJ, Spellman SR, Fleischhauer K, Hsu KC, Paczesny S, Verneris MR, et al. DONOR HLA-E STATUS ASSOCIATES WITH DISEASE FREE SURVIVAL AND TRANSPLANT RELATED MORTALITY AFTER NON IN VIVO T-CELL DEPLETED HSCT FOR ACUTE LEUKEMIA. Biol Blood Marrow Transplant. 2019.
F
Newell LF, DeFor TE, Cutler C, Verneris MR, Blazar BR, Miller JS, Antin JH, Howard A, Wu J, MacMillan ML, et al. Follistatin and Soluble Endoglin Predict 1-year Non-Relapse Mortality after Allogeneic Hematopoietic Cell Transplant. Biol Blood Marrow Transplant. 2019.
I
Verneris MR, Miller JS, Hsu KC, Wang T, Sees JA, Paczesny S, Rangarajan H, Lee DA, Spellman SR, Lee SJ. Investigation of donor KIR content and matching in children undergoing hematopoietic cell transplantation for acute leukemia. Blood Adv. 2020;4(7):1350-1356.
M
Turcotte LM, Cao Q, Cooley SA, Curtsinger J, Holtan SG, Luo X, Yingst A, Weisdorf DJ, Blazar BR, Miller JS, et al. Monocyte subpopulation recovery as predictors of hematopoietic cell transplantation outcomes. Biol Blood Marrow Transplant. 2019.
O
Wagner JE, Eapen M, Carter S, Wang Y, Schultz KR, Wall DA, Bunin N, Delaney C, Haut P, Margolis D, et al. One-Unit versus Two-Unit Cord-Blood Transplantation for Hematologic Cancers. N Engl J Med. 2014;371(18):1685-1694.
Lund TC, Ahn KWoo, Tecca HR, Hilgers MV, Abdel-Azim H, Abraham A, Díaz MÁngel, Badawy SM, Broglie L, Brown V, et al. Outcomes After Second Hematopoietic Cell Transplant for Children and Young Adults with Relapsed Acute Leukemia. Biol Blood Marrow Transplant. 2018.
P
McNerney KO, Moskop A, Winestone LE, Baggott C, Talano J-A, Schiff D, Rossoff J, Modi A, Verneris MR, Laetsch TW, et al. Practice preferences for consolidative HSCT following tisagenlecleucel in children and young adults with B-ALL. Transplant Cell Ther. 2023.
Turcotte LM, Wang T, Hemmer MT, Spellman SR, Arora M, Yingst A, Couriel D, Alousi A, Pidala J, Knight JM, et al. Pro-inflammatory Cytokine and Adipokine Levels in Adult Unrelated Marrow Donors Are Not Associated with Hematopoietic Cell Transplantation Outcomes. Biol Blood Marrow Transplant. 2018.
S
Shim S-H, Tufa D, Woods R, George TD, Shank T, Yingst A, Lake J, Cobb L, Jones D, Jones K, et al. SAHA Enhances Differentiation of CD34+CD45+ Hematopoietic Stem and Progenitor Cells from Pluripotent Stem Cells Concomitant with an Increase in Hemogenic Endothelium. Stem Cells Transl Med. 2022.
T
Barsan V, Li Y, Prabhu S, Baggott C, Nguyen K, Pacenta H, Phillips CL, Rossoff J, Stefanski H, Talano J-A, et al. Tisagenlecleucel utilisation and outcomes across refractory, first relapse and multiply relapsed B-cell acute lymphoblastic leukemia: a retrospective analysis of real-world patterns. EClinicalMedicine. 2023;65:102268.